What Is Tirzepatide?

Most people are familiar with GLP-1 (glucagon-like peptide-1) medications like semaglutide, which mimic a gut hormone that helps regulate blood sugar and appetite. Tirzepatide goes a step further: it activates receptors for two hormones — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 — making it the first dual agonist of its kind to reach the market.

In practical terms, this dual action:

• Slows gastric emptying, which increases feelings of fullness after eating
• Reduces appetite and food intake by acting on hunger signals in the brain
• Improves insulin sensitivity and helps regulate blood sugar levels
• Supports meaningful, sustained weight loss when combined with diet and exercise changes

Because it engages two hormonal pathways instead of one, tirzepatide has shown larger average weight-loss and blood-sugar results in clinical trials compared to single-agonist GLP-1 medications — though individual results vary considerably.

As of 2026, tirzepatide carries three FDA-approved indications:

Tirzepatide does not currently carry an FDA-approved cardiovascular risk-reduction indication, and any use outside these three approved indications would be considered off-label.

Weight. In the SURMOUNT-1 trial, adults with obesity taking tirzepatide at the highest dose lost an average of about 21% of body weight over 72 weeks, versus roughly 3% on placebo. Individual results varied widely.

Blood sugar. Across the SURPASS program in type 2 diabetes, tirzepatide produced HbA1c reductions that generally exceeded other medications it was tested against, including semaglutide in the SURPASS-2 head-to-head trial.

Sleep apnea. In the SURMOUNT-OSA trials, tirzepatide significantly reduced the number of breathing interruptions per hour in adults with moderate-to-severe obstructive sleep apnea and obesity, leading to its approval for that indication under the Zepbound brand.

Tirzepatide is administered as a once-weekly subcutaneous injection, typically starting at a low dose and titrated upward over time under a prescriber's guidance to balance effectiveness with tolerability.

Because appropriate starting doses, titration schedules, and target doses depend on individual health history, this is always determined by a licensed prescriber — not something to self-select.

The most frequently reported side effects are gastrointestinal and tend to be dose-dependent, often easing as the body adjusts:

• Nausea
• Diarrhea or constipation
• Vomiting
• Decreased appetite
• Injection site reactions

Tirzepatide carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies; its relevance to humans hasn't been established, but it's why the medication isn't recommended for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). As with any prescription medication, a full medical history review with a licensed provider is an essential first step.

Between 2022 and late 2024, tirzepatide was on the FDA's drug shortage list, which allowed licensed compounding pharmacies to produce copies to fill the supply gap. The FDA has since declared the shortage resolved, and compounding of tirzepatide is now generally restricted to narrow cases of documented clinical need that the FDA-approved product can't meet — such as a verified allergy to an excipient in Mounjaro or Zepbound.

Patients considering GLP-1 therapy should understand that the regulatory landscape here has shifted meaningfully since 2024, and should work with a licensed provider who can speak to what's currently permissible.

Tirzepatide isn't a standalone solution — it's most effective as part of a broader plan that includes nutrition, movement, and ongoing clinical support. Whether it's an appropriate option depends on individual health history, goals, and risk factors, which is why treatment decisions should always be made with a licensed healthcare provider who can evaluate your specific situation.